Abstract
Platelets possess two receptors for ADP, P2Y1 and P2Y12. ADP is released from platelet dense granules upon platelet activation by numerous agonists and thereby amplifies platelet responses regardless of the initial stimulus. The P2Y1 receptor is one of many platelet receptors coupled to Gq and initiates ADP-induced activation. The P2Y12 receptor on the other hand is linked to Gi and plays a special role in the amplification of platelet activation initiated by numerous other pathways. Platelet activation leads to a range of responses that play a critical role in arterial thrombosis and the inflammatory responses associated with this, including platelet aggregation, dense and α granule secretion and procoagulant activity. P2Y12 receptor activation yields powerful amplification of these processes such that P2Y12 receptor antagonists may have dramatic inhibitory effects on platelet function regardless of the activating stimuli. This phenomenon, coupled with the restricted distribution of the P2Y12 receptor in humans, makes the receptor an ideal target for pharmaceutical therapy. This has already been established by the therapeutic success of clopidogrel, which acts, via an active metabolite, on this receptor. However, current therapeutic regimens of clopidogrel yield variable and incomplete P2Y12 receptor blockade and more effective strategies to block P2Y12 receptor activation offer the potential of greater clinical efficacy.
Keywords: receptor-operated cation channel, antiplatelet effects, ATP, clopidogrel, Platelet activation
Current Pharmaceutical Design
Title: Biology and Pharmacology of the Platelet P2Y12 Receptor
Volume: 12 Issue: 10
Author(s): Robert F. Storey
Affiliation:
Keywords: receptor-operated cation channel, antiplatelet effects, ATP, clopidogrel, Platelet activation
Abstract: Platelets possess two receptors for ADP, P2Y1 and P2Y12. ADP is released from platelet dense granules upon platelet activation by numerous agonists and thereby amplifies platelet responses regardless of the initial stimulus. The P2Y1 receptor is one of many platelet receptors coupled to Gq and initiates ADP-induced activation. The P2Y12 receptor on the other hand is linked to Gi and plays a special role in the amplification of platelet activation initiated by numerous other pathways. Platelet activation leads to a range of responses that play a critical role in arterial thrombosis and the inflammatory responses associated with this, including platelet aggregation, dense and α granule secretion and procoagulant activity. P2Y12 receptor activation yields powerful amplification of these processes such that P2Y12 receptor antagonists may have dramatic inhibitory effects on platelet function regardless of the activating stimuli. This phenomenon, coupled with the restricted distribution of the P2Y12 receptor in humans, makes the receptor an ideal target for pharmaceutical therapy. This has already been established by the therapeutic success of clopidogrel, which acts, via an active metabolite, on this receptor. However, current therapeutic regimens of clopidogrel yield variable and incomplete P2Y12 receptor blockade and more effective strategies to block P2Y12 receptor activation offer the potential of greater clinical efficacy.
Export Options
About this article
Cite this article as:
Storey F. Robert, Biology and Pharmacology of the Platelet P2Y12 Receptor, Current Pharmaceutical Design 2006; 12 (10) . https://dx.doi.org/10.2174/138161206776361318
DOI https://dx.doi.org/10.2174/138161206776361318 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Proinflammatory Gene Polymorphisms and Ischemic Stroke
Current Pharmaceutical Design Critical Review of the Ankle Brachial Index
Current Cardiology Reviews Pharmacotherapy and Prevention of Vascular Dementia
CNS & Neurological Disorders - Drug Targets Phytochemical Genistein in the Regulation of Vascular Function: New Insights
Current Medicinal Chemistry A Review on Solvent-free Methods in Organic Synthesis
Current Organic Chemistry Pathophysiological Roles of Nitric Oxide: In the Heart and the Coronary Vasculature
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Current Approach to the Diagnosis and Treatment of Femoral-Popliteal Arterial Disease. A Systematic Review
Current Cardiology Reviews Membrane and Soluble Forms of Endoglin in Preeclampsia
Current Molecular Medicine The Role for Oxidative Stress in Aberrant DNA Methylation in Alzheimer’s Disease
Current Alzheimer Research Editorial [Hot topic: Sleep Abnormalities in Pulmonary Disease (Guest Editor: Shyamsunder Subramanian)]
Current Respiratory Medicine Reviews Porphyromonas Gingivalis Antigenic Determinants - Potential Targets for the Vaccine Development against Periodontitis
Infectious Disorders - Drug Targets Therapeutic Angiogenesis by Gene Therapy for Critical Limb Ischemia: Choice of Biological Agent
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cardioembolic Stroke: Clinical Features, Specific Cardiac Disorders and Prognosis
Current Cardiology Reviews Emerging Therapeutic Targets and Agents for Glioblastoma Migrating Cells
Anti-Cancer Agents in Medicinal Chemistry Cardiovascular Pharmacogenetics of Anti-Thrombotic Agents and Non-Steroidal Anti-Inflammatory Drugs
Current Molecular Medicine The Role of Diabetes Mellitus in Diseases of the Gallbladder and Biliary Tract
Current Diabetes Reviews Effect of Androgenic and Antiandrogenic Acting Compounds in Macrophage Accumulation and Cell Replication in the Aorta of Oophorectomized Hypercholesterolemic Rabbits
Vascular Disease Prevention (Discontinued) Reactive Oxygen Species and Antioxidants in the Pathophysiology of Cardiovascular Disease: Does the Actual Knowledge Justify a Clinical Approach?
Current Vascular Pharmacology Cardiovascular Disease Burden and Risk Factors Before and After Kidney Transplant
Cardiovascular & Hematological Disorders-Drug Targets Cardiorenal Consequences of Atherosclerosis and Statins Therapy: From the Past to the Future
Current Pharmaceutical Design